Prostratin
Based on 4 publication(s) in Google Scholar
Prostratin, a natural terpenoid compound, is a PKC activator, with a Ki of 12.5 nM and shows inhibitory effect on HIV-1.
For research use only. We do not sell to patients.
- Purity: 99.60%
- CAS No.: 60857-08-1
- Formula: C22H30O6
- Molecular Weight:390.47
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Prostratin
More
Customer Validation & Images
-
Flow Cytometry
Biological Activity
|
PKC 12.5 nM (Ki) |
HIV-1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| C8166 | CC50 |
>0.51 μM
Compound: 4, Prostratin
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 21534540] |
| CEM-SS | EC50 |
<=0.132 μM
Compound: Prostratin
|
Antiviral activity against HIV1 in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against HIV1 in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 11430019] |
| COLO 205 | GI50 |
1.9 x 10-6 M
Compound: Prostratin
|
Tested for growth inhibition against COLO 205 cells.
Tested for growth inhibition against COLO 205 cells.
|
[PMID: 10715158] |
| Jurkat | CC50 |
>10 μM
Compound: Prostratin
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by Ghost dye 780 staining based flow cytometric analysis
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by Ghost dye 780 staining based flow cytometric analysis
|
[PMID: 37224601] |
| KB | IC50 |
1000 μg/mL
Compound: 11
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 17512094] |
| MT2 | CC50 |
>50 μM
Compound: Prostratin
|
Cytotoxicity against human MT2 cells by Celltiter-Glo assay
Cytotoxicity against human MT2 cells by Celltiter-Glo assay
|
[PMID: 28925702] |
| MT4 | EC50 |
0.9 μM
Compound: 23, prostratin
|
Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 25970561] |
| MT4 | EC50 |
1.9 μM
Compound: 23, prostratin
|
Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 25970561] |
| PBMC | CC50 |
>100 μM
Compound: Prostratin
|
Toxicity in human PBMC assessed as reduction in cell viability after 5 days by WST8 assay
Toxicity in human PBMC assessed as reduction in cell viability after 5 days by WST8 assay
|
[PMID: 30413535] |
| Ramos | IC50 |
0.056 μg/mL
Compound: 9
|
Cytotoxicity against human Ramos B cells after 72 hrs by MTT assay
Cytotoxicity against human Ramos B cells after 72 hrs by MTT assay
|
[PMID: 16792421] |
| U-937 | CC50 |
>100 μM
Compound: Prostratin
|
Toxicity in human U-937 cells assessed as reduction in cell viability after 48 hrs by WST8 assay
Toxicity in human U-937 cells assessed as reduction in cell viability after 48 hrs by WST8 assay
|
[PMID: 30413535] |
| Vero | CC50 |
79 μM
Compound: 2
|
Cytotoxicity against african green monkey Vero cells by MTS assay
Cytotoxicity against african green monkey Vero cells by MTS assay
|
[PMID: 23215460] |
| Vero | EC50 |
>256 μM
Compound: 2
|
Antiviral activity against Semliki forest virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
Antiviral activity against Semliki forest virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
|
[PMID: 23215460] |
| Vero | EC50 |
>256 μM
Compound: 2
|
Antiviral activity against Sindbis virus HRsp infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
Antiviral activity against Sindbis virus HRsp infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
|
[PMID: 23215460] |
| Vero | EC50 |
2.6 μM
Compound: 2
|
Antiviral activity against Chikungunya virus 899 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
Antiviral activity against Chikungunya virus 899 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay
|
[PMID: 23215460] |
| Vero | EC50 |
2.7 μM
Compound: 23, prostratin
|
Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days
Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days
|
[PMID: 25970561] |
| Vero | CC50 |
79 μM
Compound: Prostratin
|
Cytotoxicity against African green monkey Vero cells assessed as morphological changes by microscopic method
Cytotoxicity against African green monkey Vero cells assessed as morphological changes by microscopic method
|
[PMID: 28925702] |
Prostratin inhibits [3H]PDBu binding to the CEM cells with a Ki of 210 nM[1].
Prostratin (125-1000 nM) dose-dependently inhibits the growth of acute myeloid leukemia (AML) cell lines (HL-60, NB4, and U937 cells). Prostratin (125-100 nM) induces G1 arrest of AML cells and affects the cell-cycle-related molecules (pRb phosphorylation, CDKs, and p21) in HL-60 cells. Prostratin also causes differentiation in AML cell lines via activation of PKC. Furthermore, PKC-dependent activation of the MEK/ERK/MAP signaling pathway requires differentiation induced by Prostratin[2].
Prostratin induces HIV-1 transcription activation requiring active form of PKD3. Prostratin also activates PKD3 via PKCε of novel PKC subfamily[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60, NB4 and U937 cells
-
Concentration:125 nM, 250 nM, 500 nM, 1000 nM
-
Incubation Time:24 hours, 48 hours, 72 hours
-
Result:Dose-dependently inhibited the growth of acute myeloid leukemia (AML) cell lines.
-
Cell Line:HL-60, NB4 and U937 cells
-
Concentration:125 nM, 250 nM, 500 nM, 1000 nM
-
Incubation Time:24 hours
-
Result:Induced a G0/G1 phase accumulation in a concentration-dependent manner.
-
Cell Line:HL-60 cells
-
Concentration:125 nM, 250 nM, 500 nM, 1000 nM
-
Incubation Time:24 hours
-
Result:Affected the cell-cycle-related molecules (pRb phosphorylation, CDKs, and p21) in HL-60 cells.
Chemical Information
-
CAS No. 60857-08-1
-
Appearance Solid
-
Molecular Weight 390.47
-
Formula C22H30O6
-
Color White to off-white
-
SMILES
CC(O[C@@]12[C@@]([C@@]3([H])[C@]([C@@H](C2)C)([C@@]4([H])[C@](CC(CO)=C3)(C(C(C)=C4)=O)O)O)([H])C1(C)C)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Carbohydr Polym
λ-Carrageenan inhibits African swine fever virus infection potentially through its interaction with the viral envelope protein CD2v. [Abstract]2026 Jun 1:381:125142. PMID: 41943364 -
J Inflamm Res
2025 Apr 30:18:5759-5775. PMID: 40322534
Prostratin purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 30:18:5759-5775. [Abstract]
In vitro experiments, we observed that the addition of the PKC-β activator Prostratin (12.5 nM) led to an increase in the proportion of Th17 cells, whereas the addition of the PKC-β inhibitor GO6983 resulted in a decrease in the proportion of Th17 cells.
-
J Proteome Res
Chemoproteomics Reveals FAM114A2 as a Functional Target of Wikstroelide E for Reversal of HIV-1 Latency. [Abstract]2025 Oct 23. PMID: 41131870 -
Mol Immunol
Formononetin in Jiawei Qihuangyin inhibits podocyte epithelial-mesenchymal transition and ameliorates diabetic nephropathy via SIRT1/NF-κB axis. [Abstract]2026 Feb:190:1-10. PMID: 41483656
Solvent & Solubility
DMSO : 50 mg/mL (128.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Gustafson KR, et al. A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. [Content Brief]
[2]. Shen X, et al. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents. Cancer Lett. 2015 Jan 28;356(2 Pt B):686-96. [Content Brief]
[3]. Wang H, et al. Protein kinase D3 is essential for prostratin-activated transcription of integrated HIV-1 provirus promoter via NF-κB signaling pathway. Biomed Res Int. 2014;2014:968027. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5610 mL | 12.8051 mL | 25.6102 mL | 64.0254 mL |
| 5 mM | 0.5122 mL | 2.5610 mL | 5.1220 mL | 12.8051 mL | |
| 10 mM | 0.2561 mL | 1.2805 mL | 2.5610 mL | 6.4025 mL | |
| 15 mM | 0.1707 mL | 0.8537 mL | 1.7073 mL | 4.2684 mL | |
| 20 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL | 3.2013 mL | |
| 25 mM | 0.1024 mL | 0.5122 mL | 1.0244 mL | 2.5610 mL | |
| 30 mM | 0.0854 mL | 0.4268 mL | 0.8537 mL | 2.1342 mL | |
| 40 mM | 0.0640 mL | 0.3201 mL | 0.6403 mL | 1.6006 mL | |
| 50 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.2805 mL | |
| 60 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.0671 mL | |
| 80 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL | |
| 100 mM | 0.0256 mL | 0.1281 mL | 0.2561 mL | 0.6403 mL |
Prostratin Related Classifications
HY-107421 Related Classifications
Powered by Bioz